Global Biosimilar Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.

According to APO Research, The global Biosimilar Insulin market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Biosimilar Insulin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Biosimilar Insulin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Biosimilar Insulin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Biosimilar Insulin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Biosimilar Insulin include Eli Lilly, Sanofi, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon and Wockhardt, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Biosimilar Insulin, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Biosimilar Insulin, also provides the sales of main regions and countries. Of the upcoming market potential for Biosimilar Insulin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biosimilar Insulin sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biosimilar Insulin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Biosimilar Insulin sales, projected growth trends, production technology, application and end-user industry.


Biosimilar Insulin Segment by Company


Eli Lilly

Sanofi

Gan&Lee

Tonghua Dongbao

United Laboratory

Geropharm

Biocon

Wockhardt

Biosimilar Insulin Segment by Type


Biosimilar Insulin Glargine

Biosimilar Insulin Lispro

Other

Biosimilar Insulin Segment by Distribution Channel

Hospital

Retail Pharmacy

Others

Biosimilar Insulin Segment by Region


North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Insulin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biosimilar Insulin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilar Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biosimilar Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Biosimilar Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview

1.1 Product Definition
1.2 Global Biosimilar Insulin Market Size, 2020 VS 2024 VS 2031
1.3 Global Biosimilar Insulin Market Size Estimates and Forecasts (2020-2031)
1.4 Global Biosimilar Insulin Sales Estimates and Forecasts (2020-2031)
1.5 Global Biosimilar Insulin Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Biosimilar Insulin Market Dynamics

2.1 Biosimilar Insulin Industry Trends
2.2 Biosimilar Insulin Industry Drivers
2.3 Biosimilar Insulin Industry Opportunities and Challenges
2.4 Biosimilar Insulin Industry Restraints
3 Biosimilar Insulin Market by Manufacturers

3.1 Global Biosimilar Insulin Revenue by Manufacturers (2020-2025)
3.2 Global Biosimilar Insulin Sales by Manufacturers (2020-2025)
3.3 Global Biosimilar Insulin Average Sales Price by Manufacturers (2020-2025)
3.4 Global Biosimilar Insulin Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Biosimilar Insulin Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Biosimilar Insulin Manufacturers, Product Type & Application
3.7 Global Biosimilar Insulin Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Biosimilar Insulin Market CR5 and HHI
3.8.2 Global Top 5 and 10 Biosimilar Insulin Players Market Share by Revenue in 2024
3.8.3 2024 Biosimilar Insulin Tier 1, Tier 2, and Tier 3
4 Biosimilar Insulin Market by Type

4.1 Biosimilar Insulin Type Introduction
4.1.1 Biosimilar Insulin Glargine
4.1.2 Biosimilar Insulin Lispro
4.1.3 Other
4.2 Global Biosimilar Insulin Sales by Type
4.2.1 Global Biosimilar Insulin Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Biosimilar Insulin Sales by Type (2020-2031)
4.2.3 Global Biosimilar Insulin Sales Market Share by Type (2020-2031)
4.3 Global Biosimilar Insulin Revenue by Type
4.3.1 Global Biosimilar Insulin Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Biosimilar Insulin Revenue by Type (2020-2031)
4.3.3 Global Biosimilar Insulin Revenue Market Share by Type (2020-2031)
5 Biosimilar Insulin Market by Application

5.1 Biosimilar Insulin Application Introduction
5.1.1 Hospital
5.1.2 Retail Pharmacy
5.1.3 Others
5.2 Global Biosimilar Insulin Sales by Application
5.2.1 Global Biosimilar Insulin Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Biosimilar Insulin Sales by Application (2020-2031)
5.2.3 Global Biosimilar Insulin Sales Market Share by Application (2020-2031)
5.3 Global Biosimilar Insulin Revenue by Application
5.3.1 Global Biosimilar Insulin Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Biosimilar Insulin Revenue by Application (2020-2031)
5.3.3 Global Biosimilar Insulin Revenue Market Share by Application (2020-2031)
6 Global Biosimilar Insulin Sales by Region

6.1 Global Biosimilar Insulin Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Biosimilar Insulin Sales by Region (2020-2031)
6.2.1 Global Biosimilar Insulin Sales by Region (2020-2025)
6.2.2 Global Biosimilar Insulin Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Biosimilar Insulin Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Biosimilar Insulin Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Biosimilar Insulin Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Biosimilar Insulin Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Biosimilar Insulin Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Biosimilar Insulin Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Biosimilar Insulin Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Biosimilar Insulin Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Biosimilar Insulin Revenue by Region

7.1 Global Biosimilar Insulin Revenue by Region
7.1.1 Global Biosimilar Insulin Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Biosimilar Insulin Revenue by Region (2020-2025)
7.1.3 Global Biosimilar Insulin Revenue by Region (2026-2031)
7.1.4 Global Biosimilar Insulin Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Biosimilar Insulin Revenue (2020-2031)
7.2.2 North America Biosimilar Insulin Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Biosimilar Insulin Revenue (2020-2031)
7.3.2 Europe Biosimilar Insulin Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Biosimilar Insulin Revenue (2020-2031)
7.4.2 Asia-Pacific Biosimilar Insulin Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Biosimilar Insulin Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Biosimilar Insulin Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles

8.1 Eli Lilly
8.1.1 Eli Lilly Comapny Information
8.1.2 Eli Lilly Business Overview
8.1.3 Eli Lilly Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Eli Lilly Biosimilar Insulin Product Portfolio
8.1.5 Eli Lilly Recent Developments
8.2 Sanofi
8.2.1 Sanofi Comapny Information
8.2.2 Sanofi Business Overview
8.2.3 Sanofi Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Sanofi Biosimilar Insulin Product Portfolio
8.2.5 Sanofi Recent Developments
8.3 Gan&Lee
8.3.1 Gan&Lee Comapny Information
8.3.2 Gan&Lee Business Overview
8.3.3 Gan&Lee Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Gan&Lee Biosimilar Insulin Product Portfolio
8.3.5 Gan&Lee Recent Developments
8.4 Tonghua Dongbao
8.4.1 Tonghua Dongbao Comapny Information
8.4.2 Tonghua Dongbao Business Overview
8.4.3 Tonghua Dongbao Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Tonghua Dongbao Biosimilar Insulin Product Portfolio
8.4.5 Tonghua Dongbao Recent Developments
8.5 United Laboratory
8.5.1 United Laboratory Comapny Information
8.5.2 United Laboratory Business Overview
8.5.3 United Laboratory Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 United Laboratory Biosimilar Insulin Product Portfolio
8.5.5 United Laboratory Recent Developments
8.6 Geropharm
8.6.1 Geropharm Comapny Information
8.6.2 Geropharm Business Overview
8.6.3 Geropharm Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Geropharm Biosimilar Insulin Product Portfolio
8.6.5 Geropharm Recent Developments
8.7 Biocon
8.7.1 Biocon Comapny Information
8.7.2 Biocon Business Overview
8.7.3 Biocon Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Biocon Biosimilar Insulin Product Portfolio
8.7.5 Biocon Recent Developments
8.8 Wockhardt
8.8.1 Wockhardt Comapny Information
8.8.2 Wockhardt Business Overview
8.8.3 Wockhardt Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Wockhardt Biosimilar Insulin Product Portfolio
8.8.5 Wockhardt Recent Developments
9 Value Chain and Sales Channels Analysis

9.1 Biosimilar Insulin Value Chain Analysis
9.1.1 Biosimilar Insulin Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Biosimilar Insulin Production Mode & Process
9.2 Biosimilar Insulin Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Biosimilar Insulin Distributors
9.2.3 Biosimilar Insulin Customers
10 Concluding Insights
11 Appendix

11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings